scholarly journals Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Andrea Marzi ◽  
Aisling A. Murphy ◽  
Friederike Feldmann ◽  
Christopher J. Parkins ◽  
Elaine Haddock ◽  
...  
Keyword(s):  
Virus Infection ◽  
Nonhuman Primates ◽  
Ebola Virus ◽  
Virus Glycoprotein ◽  
Ebola Virus Infection

scholarly journals Clinical Laboratory Values as Early Indicators of Ebola Virus Infection in Nonhuman Primates

2017 ◽  
Vol 23 (8) ◽  
pp. 1316-1324 ◽  
Author(s):  
Ronald B. Reisler ◽  
Chenggang Yu ◽  
Michael J. Donofrio ◽  
Travis K. Warren ◽  
Jay B. Wells ◽  
...  
Keyword(s):  
Virus Infection ◽  
Nonhuman Primates ◽  
Ebola Virus ◽  
Clinical Laboratory ◽  
Laboratory Values ◽  
Ebola Virus Infection ◽  
Early Indicators

scholarly journals Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates

2012 ◽  
Vol 4 (158) ◽  
pp. 158ra146-158ra146 ◽  
Author(s):  
G. Wong ◽  
J. S. Richardson ◽  
S. Pillet ◽  
A. Patel ◽  
X. Qiu ◽  
...  
Keyword(s):  
Virus Infection ◽  
Nonhuman Primates ◽  
Ebola Virus ◽  
Immune Parameters ◽  
Ebola Virus Infection

scholarly journals Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb

2013 ◽  
Vol 3 (1) ◽  
Author(s):  
Xiangguo Qiu ◽  
Jonathan Audet ◽  
Gary Wong ◽  
Lisa Fernando ◽  
Alexander Bello ◽  
...  
Keyword(s):  
Virus Infection ◽  
Nonhuman Primates ◽  
Ebola Virus ◽  
Ebola Virus Infection

CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates

2011 ◽  
Vol 17 (9) ◽  
pp. 1128-1131 ◽  
Author(s):  
Nancy J Sullivan ◽  
Lisa Hensley ◽  
Clement Asiedu ◽  
Thomas W Geisbert ◽  
Daphne Stanley ◽  
...  
Keyword(s):  
Virus Infection ◽  
Cellular Immunity ◽  
Nonhuman Primates ◽  
Ebola Virus ◽  
Vaccine Protection ◽  
Ebola Virus Infection

scholarly journals A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates

2015 ◽  
Vol 212 (suppl 2) ◽  
pp. S368-S371 ◽  
Author(s):  
Oleg V. Pyankov ◽  
Sergey A. Bodnev ◽  
Olga G. Pyankova ◽  
Vladislav V. Solodkyi ◽  
Stepan A. Pyankov ◽  
...  
Keyword(s):  
Virus Infection ◽  
Nonhuman Primates ◽  
Ebola Virus ◽  
Virus Like Particle ◽  
Ebola Virus Infection

scholarly journals A Serological Survey of Ebola Virus Infection in Central African Nonhuman Primates

2004 ◽  
Vol 190 (11) ◽  
pp. 1895-1899 ◽  
Author(s):  
E. M. Leroy ◽  
P. Telfer ◽  
B. Kumulungui ◽  
P. Yaba ◽  
P. Rouquet ◽  
...  
Keyword(s):  
Virus Infection ◽  
Nonhuman Primates ◽  
Ebola Virus ◽  
Serological Survey ◽  
Ebola Virus Infection

scholarly journals Pathogenesis of Ebola Virus Infection in Nonhuman Primates

Uirusu ◽  
2003 ◽  
Vol 53 (1) ◽  
pp. 55-55
Author(s):  
Thomas W. Geisbert ◽  
Lisa E. Hensley ◽  
Howard A. Young ◽  
Doug Reed ◽  
Kelly J. Davis ◽  
...  
Keyword(s):  
Virus Infection ◽  
Nonhuman Primates ◽  
Ebola Virus ◽  
Ebola Virus Infection

scholarly journals Identification of Protective Epitopes on Ebola Virus Glycoprotein at the Single Amino Acid Level by Using Recombinant Vesicular Stomatitis Viruses

2003 ◽  
Vol 77 (2) ◽  
pp. 1069-1074 ◽  
Author(s):  
Ayato Takada ◽  
Heinz Feldmann ◽  
Ute Stroeher ◽  
Mike Bray ◽  
Shinji Watanabe ◽  
...  
Keyword(s):  
Amino Acid ◽  
Virus Infection ◽  
Ebola Virus ◽  
Hemorrhagic Fever ◽  
Passive Transfer ◽  
Single Amino Acid ◽  
Virus Glycoprotein ◽  
Vesicular Stomatitis ◽  
Encoding Gene ◽  
Ebola Virus Infection

ABSTRACT Ebola virus causes lethal hemorrhagic fever in humans, but currently there are no effective vaccines or antiviral compounds for this infectious disease. Passive transfer of monoclonal antibodies (MAbs) protects mice from lethal Ebola virus infection (J. A. Wilson, M. Hevey, R. Bakken, S. Guest, M. Bray, A. L. Schmaljohn, and M. K. Hart, Science 287:1664-1666, 2000). However, the epitopes responsible for neutralization have been only partially characterized because some of the MAbs do not recognize the short synthetic peptides used for epitope mapping. To identify the amino acids recognized by neutralizing and protective antibodies, we generated a recombinant vesicular stomatitis virus (VSV) containing the Ebola virus glycoprotein-encoding gene instead of the VSV G protein-encoding gene and used it to select escape variants by growing it in the presence of a MAb (133/3.16 or 226/8.1) that neutralizes the infectivity of the virus. All three variants selected by MAb 133/3.16 contained a single amino acid substitution at amino acid position 549 in the GP2 subunit. By contrast, MAb 226/8.1 selected three different variants containing substitutions at positions 134, 194, and 199 in the GP1 subunit, suggesting that this antibody recognized a conformational epitope. Passive transfer of each of these MAbs completely protected mice from a lethal Ebola virus infection. These data indicate that neutralizing antibody cocktails for passive prophylaxis and therapy of Ebola hemorrhagic fever can reduce the possibility of the emergence of antigenic variants in infected individuals.

scholarly journals Kunjin Virus Replicon-Based Vaccines Expressing Ebola Virus Glycoprotein GP Protect the Guinea Pig Against Lethal Ebola Virus Infection

2011 ◽  
Vol 204 (suppl_3) ◽  
pp. S1060-S1065 ◽  
Author(s):  
O. Reynard ◽  
V. Mokhonov ◽  
E. Mokhonova ◽  
J. Leung ◽  
A. Page ◽  
...  
Keyword(s):  
Virus Infection ◽  
Guinea Pig ◽  
Ebola Virus ◽  
Virus Glycoprotein ◽  
Ebola Virus Infection

scholarly journals Profiling the Native Specific Human Humoral Immune Response to Sudan Ebola Virus Strain Gulu by Chemiluminescence Enzyme-Linked Immunosorbent Assay

2012 ◽  
Vol 19 (11) ◽  
pp. 1844-1852 ◽  
Author(s):  
Ariel Sobarzo ◽  
Eddie Perelman ◽  
Allison Groseth ◽  
Olga Dolnik ◽  
Stephan Becker ◽  
...  
Keyword(s):  
Virus Infection ◽  
Immunosorbent Assay ◽  
Nonhuman Primates ◽  
Ebola Virus ◽  
Viral Proteins ◽  
Enzyme Linked Immunosorbent Assay ◽  
Viral Glycoprotein ◽  
Lethal Challenge ◽  
Content Type ◽  
Ebola Virus Infection

ABSTRACTEbolavirus, a member of the familyFiloviridae, causes high lethality in humans and nonhuman primates. Research focused on protection and therapy for Ebola virus infection has investigated the potential role of antibodies. Recent evidence suggests that antibodies can be effective in protection from lethal challenge with Ebola virus in nonhuman primates. However, despite these encouraging results, studies have not yet determined the optimal antibodies and composition of an antibody cocktail, if required, which might serve as a highly effective and efficient prophylactic. To better understand optimal antibodies and their targets, which might be important for protection from Ebola virus infection, we sought to determine the profile of viral protein-specific antibodies generated during a natural cycle of infection in humans. To this end, we characterized the profile of antibodies against individual viral proteins of Sudan Ebola virus (Gulu) in human survivors and nonsurvivors of the outbreak in Gulu, Uganda, in 2000-2001. We developed a unique chemiluminescence enzyme-linked immunosorbent assay (ELISA) for this purpose based on the full-length recombinant viral proteins NP, VP30, and VP40 and two recombinant forms of the viral glycoprotein (GP1-294and GP1-649) of Sudan Ebola virus (Gulu). Screening results revealed that the greatest immunoreactivity was directed to the viral proteins NP and GP1-649, followed by VP40. Comparison of positive immunoreactivity between the viral proteins NP, GP1-649, and VP40 demonstrated a high correlation of immunoreactivity between these viral proteins, which is also linked with survival. Overall, our studies of the profile of immunorecognition of antibodies against four viral proteins of Sudan Ebola virus in human survivors may facilitate development of effective monoclonal antibody cocktails in the future.

Sign in / Sign up

Export Citation Format

Share Document